Literature DB >> 28927131

Protein expression of Fragile Histidine Triad and cyclooxgenase-2 in serrated neoplasia of the colorectum.

Akihiro Tamoto1, Kazuo Yashima1, Kohei Hosoda1, Sohei Yamamoto1, Soichiro Kawata1, Yuichiro Ikebuchi1, Kazuya Matsumoto1, Koichiro Kawaguchi1, Kenichi Harada1, Yoshikazu Murawaki1, Hajime Isomoto1.   

Abstract

The adenoma-carcinoma sequence (ACS) and the serrated pathway are two distinct developmental routes leading to the formation of colorectal carcinoma (CRC). However, the mechanism triggered by the serrated pathway remains unclear. Therefore, to clarify the molecular and clinicopathological characteristics of the serrated tumorigenic pathway, immunohistochemistry was used to examine the expression of Fragile Histidine Triad (FHIT), cyclooxygenase-2 (COX-2), MutL homolog 1 (MLH1), MutS protein homolog 2 (MSH2) and P53 in endoscopically resected samples of 62 serrated polyps. These samples included 20 hyperplastic polyps (HPs), 16 traditional serrated adenomas (TSAs), 26 sessile serrated adenoma/polyps (SSA/Ps), 20 non-serrated adenomas, 20 carcinoma in adenomas (CIAs) and 18 early pure CRCs without any adenoma component (EPCs). FHIT expression was markedly reduced or absent in 50% of TSA samples, 92.3% of SSA/Ps and 44% of EPCs, but only rarely in HPs, non-serrated adenomas and CIAs. COX-2 expression was more common in non-serrated adenomas compared with in serrated polyps, and was present in 25 and 3.2% of the cases respectively (P<0.01). Furthermore, COX-2 expression was more frequent in CIAs (60%) compared with in EPCs (22.2%; P<0.05). The incidence of negative COX-2 expression was higher in FHIT-negative SSA/Ps compared with in FHIT-positive SSA/Ps (P=0.08). A total of 16.7% of EPC samples and 11.5% of SSA/Ps demonstrated a loss of MLH1/MSH2 expression, but none of the other tumor types did. P53 overexpression was significantly increased in EPC (77.8%) and CIA (60%) samples compared with in HP (0%), TSA (6.6%), SSA/P (0%) and non-serrated adenoma (10%) samples (P<0.01). These findings demonstrated that there are different expression patterns between the serrated pathway and ACS, indicating that aberrant FHIT and inhibited COX-2 expression may be associated with serrated tumorigenesis. In addition, this data indicated that EPC may contain tumors derived from the serrated pathway as well as ACS.

Entities:  

Keywords:  Fragile Histidine Triad; cyclooxygenase-2; endoscopic resection; serrated pathway; sessile serrated adenoma/polyp

Year:  2017        PMID: 28927131      PMCID: PMC5587971          DOI: 10.3892/ol.2017.6634

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  35 in total

1.  Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions.

Authors:  X P Hao; J E Willis; T G Pretlow; J S Rao; G T MacLennan; I C Talbot; T P Pretlow
Journal:  Cancer Res       Date:  2000-01-01       Impact factor: 12.701

2.  Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer.

Authors:  Shuji Ogino; Mohan Brahmandam; Takako Kawasaki; Gregory J Kirkner; Massimo Loda; Charles S Fuchs
Journal:  Neoplasia       Date:  2006-06       Impact factor: 5.715

3.  General rules for clinical and pathological studies on cancer of the colon, rectum and anus. Part I. Clinical classification. Japanese Research Society for Cancer of the Colon and Rectum.

Authors: 
Journal:  Jpn J Surg       Date:  1983-11

4.  Reduced FHIT expression is associated with mismatch repair deficient and high CpG island methylator phenotype colorectal cancer.

Authors:  Rabeah Abbas Al-Temaimi; Sindhu Jacob; Waleed Al-Ali; Diana Ann Thomas; Fahd Al-Mulla
Journal:  J Histochem Cytochem       Date:  2013-06-24       Impact factor: 2.479

5.  The Vienna classification of gastrointestinal epithelial neoplasia.

Authors:  R J Schlemper; R H Riddell; Y Kato; F Borchard; H S Cooper; S M Dawsey; M F Dixon; C M Fenoglio-Preiser; J F Fléjou; K Geboes; T Hattori; T Hirota; M Itabashi; M Iwafuchi; A Iwashita; Y I Kim; T Kirchner; M Klimpfinger; M Koike; G Y Lauwers; K J Lewin; G Oberhuber; F Offner; A B Price; C A Rubio; M Shimizu; T Shimoda; P Sipponen; E Solcia; M Stolte; H Watanabe; H Yamabe
Journal:  Gut       Date:  2000-08       Impact factor: 23.059

6.  Absence of Msh2 protein expression is associated with alteration in the FHIT locus and Fhit protein expression in colorectal carcinoma.

Authors:  M Mori; K Mimori; T Masuda; K Yoshinaga; K Yamashita; A Matsuyama; H Inoue
Journal:  Cancer Res       Date:  2001-10-15       Impact factor: 12.701

7.  Progressive methylation during the serrated neoplasia pathway of the colorectum.

Authors:  Seung M Dong; Eui J Lee; Eun S Jeon; Cheol K Park; Kyoung-Mee Kim
Journal:  Mod Pathol       Date:  2005-02       Impact factor: 7.842

8.  Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability.

Authors:  J M Cunningham; E R Christensen; D J Tester; C Y Kim; P C Roche; L J Burgart; S N Thibodeau
Journal:  Cancer Res       Date:  1998-08-01       Impact factor: 12.701

9.  Expression of hMLH1 is inactivated in the gastric adenomas with enhanced microsatellite instability.

Authors:  M J Baek; H Kang; S E Kim; J H Park; J S Lee; Y K Paik; H Kim
Journal:  Br J Cancer       Date:  2001-10-19       Impact factor: 7.640

10.  Reduced Fhit expression is associated with mismatch repair deficiency in human advanced colorectal carcinoma.

Authors:  H Andachi; K Yashima; M Koda; K Kawaguchi; A Kitamura; A Hosoda; Y Kishimoto; G Shiota; H Ito; M Makino; N Kaibara; H Kawasaki; Y Murawaki
Journal:  Br J Cancer       Date:  2002-08-12       Impact factor: 7.640

View more
  1 in total

1.  Expression of doublecortin and CaM kinase-like-1 protein in serrated neoplasia of the colorectum.

Authors:  Keiko Morio; Kazuo Yashima; Akihiro Tamoto; Kohei Hosoda; Sohei Yamamoto; Taku Iwamoto; Naoki Ueda; Yuichiro Ikebuchi; Koichiro Kawaguchi; Kenichi Harada; Yoshikazu Murawaki; Hajime Isomoto
Journal:  Biomed Rep       Date:  2017-11-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.